Arena Pharmaceuticals (ARNA) 6.18 $ARNA
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
NIRI San Diego to Host Special Luncheon with LinkedIn's Head of Investor Education, Matt Sonefeldt, on May 15
PR Newswire - Tue Apr 15, 1:26PM CDT
The San Diego Chapter of the National Investor Relations Institute (NIRI) will host a special event with LinkedIn's Head of Investor Education, Matt Sonefeldt, on Thursday, May 15, 2014. The luncheon will be held at the corporate headquarters of Arena Pharmaceuticals, Inc. in San Diego, CA.
Arena Pharmaceuticals reports national television advertising campaign for BELVIQ for chronic weight management
M2 - Tue Apr 15, 5:26AM CDT
Biopharmaceutical company Arena Pharmaceuticals (NasdaqGS:ARNA) announced on Monday a national television advertising campaign on Lifetime, Oxygen, AMC and numerous other networks for BELVIQ for chronic weight management.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management
PR Newswire - Mon Apr 14, 7:33AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help patients lose weight and keep it off.
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
MannKind's Dominating Win Annihilates the Shorts
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:52PM CDT
The biggest winner in health care, and possibly on the entire market, was MannKind today, up an astonishing 73% after the advisory committee reviewing its inhalable insulin Afrezza to make its recommendation to the FDA for or against, shocked the...
Research and Markets: Global Belviq (Obesity) Report 2014 - Forecast and Market Analysis to 2022
Business Wire - Wed Apr 02, 11:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vchhpv/belviq_obesity) has announced the addition of the "Belviq (Obesity) - Forecast and Market Analysis to 2022" report to their offering.
Global Belviq (Obesity) Report 2014 - Forecast and Market Analysis to 2022
M2 - Wed Apr 02, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ph43kx/belviq_obesity) has announced the addition of the "Belviq (Obesity) - Forecast and Market Analysis to 2022" report to their offering. Belviq (lorcaserin), a product of Arena Pharmaceuticals, was the second anti-obesity drug to arrive in the market after a long pharmacotherapy hiatus, coming nine months after the launch of Vivus' Qsymia as one of the main competitors. It is not yet approved in any of the European markets, Canada, Brazil, or Japan. GlobalData forecasts that Belviq will not reach the European market until 2018, the Canadian market until 2017, and the Brazilian market until 2016. Arena and its marketing partner, Eisai, have given no indication of any plans to launch Belviq in Japan. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Belviq (lorcaserin) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix For more information visit http://www.researchandmarkets.com/research/ph...iq_obesity
Can Arena and VIVUS Profit From Glaxo's Troubles?
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:12PM CDT
Last week, GlaxoSmithKline announced that it was on recalling its over-the-counter obesity drug, Alli, in the U.S. and Puerto Rico because it appears that some packages were tampered with. The drug remains on the shelf in Europe, where there...
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
ARNA May 9th Options Begin Trading
DividendChannel.com - Thu Mar 27, 10:44AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 9th contracts and identified one...
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
NIRI San Diego to Host Special Luncheon with LinkedIn's Head of Investor Education, Matt Sonefeldt, on May 15
PR Newswire - Tue Apr 15, 1:26PM CDT
The San Diego Chapter of the National Investor Relations Institute (NIRI) will host a special event with LinkedIn's Head of Investor Education, Matt Sonefeldt, on Thursday, May 15, 2014. The luncheon will be held at the corporate headquarters of Arena Pharmaceuticals, Inc. in San Diego, CA.
Arena Pharmaceuticals reports national television advertising campaign for BELVIQ for chronic weight management
M2 - Tue Apr 15, 5:26AM CDT
Biopharmaceutical company Arena Pharmaceuticals (NasdaqGS:ARNA) announced on Monday a national television advertising campaign on Lifetime, Oxygen, AMC and numerous other networks for BELVIQ for chronic weight management.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management
PR Newswire - Mon Apr 14, 7:33AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help patients lose weight and keep it off.
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
MannKind's Dominating Win Annihilates the Shorts
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:52PM CDT
The biggest winner in health care, and possibly on the entire market, was MannKind today, up an astonishing 73% after the advisory committee reviewing its inhalable insulin Afrezza to make its recommendation to the FDA for or against, shocked the...
Research and Markets: Global Belviq (Obesity) Report 2014 - Forecast and Market Analysis to 2022
Business Wire - Wed Apr 02, 11:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vchhpv/belviq_obesity) has announced the addition of the "Belviq (Obesity) - Forecast and Market Analysis to 2022" report to their offering.
Global Belviq (Obesity) Report 2014 - Forecast and Market Analysis to 2022
M2 - Wed Apr 02, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ph43kx/belviq_obesity) has announced the addition of the "Belviq (Obesity) - Forecast and Market Analysis to 2022" report to their offering. Belviq (lorcaserin), a product of Arena Pharmaceuticals, was the second anti-obesity drug to arrive in the market after a long pharmacotherapy hiatus, coming nine months after the launch of Vivus' Qsymia as one of the main competitors. It is not yet approved in any of the European markets, Canada, Brazil, or Japan. GlobalData forecasts that Belviq will not reach the European market until 2018, the Canadian market until 2017, and the Brazilian market until 2016. Arena and its marketing partner, Eisai, have given no indication of any plans to launch Belviq in Japan. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Belviq (lorcaserin) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix For more information visit http://www.researchandmarkets.com/research/ph...iq_obesity
Can Arena and VIVUS Profit From Glaxo's Troubles?
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:12PM CDT
Last week, GlaxoSmithKline announced that it was on recalling its over-the-counter obesity drug, Alli, in the U.S. and Puerto Rico because it appears that some packages were tampered with. The drug remains on the shelf in Europe, where there...
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
ARNA May 9th Options Begin Trading
DividendChannel.com - Thu Mar 27, 10:44AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 9th contracts and identified one...
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
